Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
Eosinophilic Esophagitis (EoE)
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults with Eosinophilic Esophagitis
-
Research Site 1039, Dothan, Alabama, United States, 36305
Research Site 1015, San Diego, California, United States, 92120
Research Site 1040, Inverness, Florida, United States, 34452
Research Site 1001, Jacksonville, Florida, United States, 32256
Research Site 1004, Boston, Massachusetts, United States, 02111
Research Site 1006, Plymouth, Minnesota, United States, 55446
Research Site 1016, Reno, Nevada, United States, 89511
Research Site 1020, Harrisburg, Pennsylvania, United States, 17110
Research Site 1002, Ogden, Utah, United States, 84405
Research Site 1017, Sandy, Utah, United States, 84092
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 75 Years
ALL
No
Uniquity One (UNI),
Andrew W Lee, MD, STUDY_CHAIR, Vice President, Clinical Research
2027-08-31